Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 401–500 of 1,000
Design of a Long-Acting and Selective MEG-Fatty Acid Stapled Prolactin-Releasing Peptide Analog
Pflimlin, E., Lear, S., Lee, C., Yu, S., Zou, H., To, A., Joseph, S. B., Nguyen-Tran, V. T. B., Tremblay, M. S., & Shen, W. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00182 · Cited by 21
Pickford, P., Lucey, M., Rujan, R., McGlone, E. R., Bitsi, S., Ashford, F. B., Junior, I. R. C., Hodson, D. J., Tomás, A., Deganutti, G., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101242 · Cited by 22
“AIB2 is better tolerated by GLP-1 than G2, whilst retaining identical protection against DPP-4 mediated degradation [64], and has been incorporated into the current leading GLP-1R mono-agonist semaglutide [65].”
BackgroundVisaria, J., Uzoigwe, C., Swift, C., Dang-Tan, T., Paprocki, Y., & Willey, V. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.03.003 · Cited by 20
Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery☆
Jülke, E., & Beck‐Sickinger, A. G. (2025) · Peptides · doi:10.1016/j.peptides.2025.171404 · Cited by 20
Barać, M., & Roganović, J. (2025) · Biology · doi:10.3390/biology14121650 · Cited by 32
“Semaglutide contains a large hydrophobic fatty diacid side chain that anchors the peptide to human serum albumin [66].”
Obesity as a Neuroendocrine Reprogramming
Ghanemi, A., Yoshioka, M., & St‐Amand, J. (2021) · Medicina · doi:10.3390/medicina57010066 · Cited by 20
“In addition, the existence of pharmacological approaches targeting the nervous system to treat obesity, such as utilization of the glucagon-like peptide-1 receptor [9,20], go beyond the usage of the classical obesity-related pillars; exercise and diet [21] further indicate that the nervous system’s involvement in obes…”
BackgroundNESTOR, J. J. J., Zhang, X., Jaw‐Tsai, S., Parkes, D. G., & Becker, C. (2021) · Peptide Science · doi:10.1002/pep2.24221 · Cited by 24
Sang, P., Zeng, H., Lee, C., Shi, Y., Wang, M., Pan, C., Wei, L., Huang, C., Wu, M., Shen, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01289 · Cited by 19
Implications of ligand-receptor binding kinetics on GLP-1R signalling
Zhao, P., Truong, T. T., Merlin, J., Sexton, P. M., & Wootten, D. L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114985 · Cited by 19
A Treatment to Cure Diabetes Using Plant-Based Drug Discovery
Mahankali, S., Kalava, J., Garapati, Y., Domathoti, B., Maddumala, V. R., & Sundramurthy, V. P. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8621665 · Cited by 20
“Peptide oral delivery has been tested in the past, but its application is limited due to the fact that the GI system breaks down peptides [96].”
BackgroundPeptide Hormones in Medicine: A 100-Year History
Мартинович, В. П., & Baradzina, K. U. (2022) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162022020157 · Cited by 21
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs
Pinto, S., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1952 · Cited by 20
Han, J. D. J., Huang, Y., Chen, X., Zhou, F. L., Fei, Y., & Fu, J. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.032 · Cited by 19
Andersen, A. H. F., & Tolstrup, M. (2020) · Viruses · doi:10.3390/v12040412 · Cited by 18
“Using a lipid-polymer, such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine poly(ethylene glycol) (DSPE-PEG) with a natural affinity for albumin in vivo can solve this [94,95].”
BackgroundFighting Alzheimer's naturally: Peptides as multitarget drug leads
Spinelli, R., Sanchís, I., & Siano, Á. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130305 · Cited by 19
Chen, H., Lu, Y., Shi, S., Zhang, Q., Cao, X., Sun, L., An, D., Zhang, X., Kong, X., & Liu, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03265-3 · Cited by 20
“Compared to liraglutide, only one amino is changed in the peptide chain of semaglutide substituting α-aminobutyric acid for Ala at position 8 to avoid degradation by DPP-4 (15).”
BackgroundZhang, C., Yang, X., Meng, X., Wu, L., Liu, X., Gao, J., Liu, S., Wu, J., Huang, D., Wang, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02003 · Cited by 19
Gao, Z., Wei, Y., & Ma, G. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb02207b · Cited by 19
Smidt, J. M., Lykke, L., Stidsen, C. E., Pristovšek, N., & Gothelf, K. V. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1015 · Cited by 18
“This could be due to unfavorable interactions at the peptide N-terminal, which is crucial for GLP1R binding ( 43 ) , as the siRNA is closer to the N-terminal in peptide B. Increasing linker length in these conjugates could potentially allow for less disruption ( 33 ) .”
BackgroundMethodWestergaard, L., Alifrangis, L. H., Buckley, S. T., Coester, H. V., Klitgaard, T., Kristensen, N. R., Nishimura, E., Nørgreen, L., Rocha, T. M. P., Steensgaard, D. B., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01405-8 · Cited by 20
“The HSA binding experiments were performed essentially as described previously [15]: Sedimentation velocity experiments were performed in an XL-I analytical ultracentrifuge (BeckmanCoulter, Indianapolis, USA) at 20 °C. Solutions of 100 μM ligand, 10 μM HSA and 0–1000 μM SFAD were filled into…”
Self-citationA Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Miyata, K., Ukawa, M., Mohri, K., Fujii, K., Yamada, M., Tanishita, S., Higashitarumi, S., Ishizaki, S., Kumagai, H., Ochiai, K., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00185 · Cited by 19
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imajo, K., Saito, S., & Nakajima, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543403 · Cited by 20
“For the treatment of diabetes mellitus, it is administered once weekly [79].”
BackgroundCho, J., Park, J., Kim, S., Kim, J. C., Tae, G., Jin, M. S., & Kwon, I. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.034 · Cited by 19
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
Jiang, N., Jing, L., Li, Q., Su, S.-B., Yang, Q., Zhou, F. L., Chen, X., Han, J. D. J., Tang, C., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113118 · Cited by 20
PEGylated prodrugs of antidiabetic peptides amylin and GLP-1
Böttger, R., Knappe, D., & Hoffmann, R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.001 · Cited by 19
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17
Sun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P. (2022) · Pharmaceuticals · doi:10.3390/ph15060740 · Cited by 17
“However, the high price of chemical modification also hinders the widespread use of such drugs(Elbrond et al. 2002; Madsen et al. 2007; Lau et al. 2015).”
BackgroundArtificial lipidation of proteins and peptides: from mechanism to clinical applications
Mu, J., Vong, E., & Carmali, S. (2025) · FEBS Journal · doi:10.1111/febs.70298 · Cited by 19
“[40] explored alternative fatty diacid modifications, culminating in the C18 diacid modification of semaglutide with extended half-life properties.”
InfluentialWeiskirchen, R., & Lonardo, A. (2025) · Medical Sciences · doi:10.3390/medsci13040265 · Cited by 22
“This single change sterically hinders DPP-4, rendering the analogue essentially resistant to proteolysis and preserving its biological integrity for many hours after administration [29,32].”
InfluentialRational Development of Stable PYY3–36 Peptide Y2 Receptor Agonists
Poulsen, C., Pedersen, M. Ø., Wahlund, P., Sjölander, A., Thomsen, J. K., Conde‐Frieboes, K. W., Paulsson, J. F., Wulff, B. S., & Østergaard, S. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03077-x · Cited by 18
Jones, B. J., BURADE, V. S., Akalestou, E., Manchanda, Y., Ramchunder, Z., Carrat, G., Nguyen‐Tu, M., Marchetti, P., Piemonti, L., Leclerc, I., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14794 · Cited by 17
“assessed the binding kinetic parameters of each agonist using a competition-based assay in which binding of the fluorescent antagonist exendin(9-39)-FITC to GLP-1R is monitored in real time in the presence of varying concentrations of test agonists.”
BackgroundMethodInfluentialSemaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes
Tuchscherer, R. M., Thompson, A. M., & Trujillo, J. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018784583 · Cited by 19
Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
Chen, X., Chen, S., Ren, Q., Niu, S., Pan, X., Yue, L., Li, Z., Zhu, R., Jia, Z., Chen, X., et al. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s383537 · Cited by 18
“8,9 18–20 However, the renoprotective effect of semaglutide and its involved mechanisms remain unclear.”
Fernandes, C., Ribeiro, R., Pinto, M. M. M., & Kijjoa, A. (2023) · Molecules · doi:10.3390/molecules28020615 · Cited by 17
“Peptide half-life is expanded through lipidation, where a long-chain saturated lipid is acylated to an amino acid to facilitate its binding to a carrier serum protein [85,86].”
BackgroundDoggrell, S. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1441286 · Cited by 21
“Importantly, the second N-terminal amino acid substitution reduced the susceptibility to degradation by dipeptidyl peptidase-4 (DPP-4) making a longer-acting molecule [8].”
BackgroundVascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX
Sheykhzade, M., Abdolalizadeh, B., Koole, C., Pickering, D. S., Dreisig, K., Johansson, S. E., Abboud, B. K., Dreier, R., Berg, J. O., Jeppesen, J., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.007 · Cited by 17
Long-Acting, Potent Delivery of Combination Antiretroviral Therapy
Andersen, A. H. F., Frich, C. K., Zuwała, K., Tolstrup, M., Dagnæs‐Hansen, F., Denton, P. W., & Zelikin, A. N. (2018) · ACS Macro Letters · doi:10.1021/acsmacrolett.8b00179 · Cited by 19
Oddo, A., Mortensen, S., Thøgersen, H., Maria, L. D., Hennen, S., McGuire, J. N., Kofoed, J., Linderoth, L., & Reedtz‐Runge, S. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00105 · Cited by 17
Self-citationSensfuß, U., Kruse, T., Skyggebjerg, R. B., Uldam, H. K., Vestergaard, B., Huus, K., Vinther, T. N., Reinau, M. E., Schéele, S. G., & Clausen, T. R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01558 · Cited by 17
Self-citationHigh-Dose Once-Weekly Semaglutide: A New Option for Obesity Management
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211053867 · Cited by 16
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16
Alsheikh, A., Alshehri, A., Alzahrani, S., Jammah, A. A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01516-z · Cited by 16
“Semaglutide, a human glucagon-like peptide 1 (GLP-1) analogue and GLP-1 receptor agonist (GLP-1RA) with a lengthy half-life, can be administered once weekly (OW) [8].”
Helmy, N. M., Davani-Davari, D., & Parang, K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02390 · Cited by 18
Delayed Hypersensitivity Reaction to Liraglutide: A Case Report
Carvallo, A., Silva, C., Gastaminza, G., & D’Amelio, C. (2020) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0521 · Cited by 16
“0521 arginine at position 34 and acylation of lysine at position 26 with a stearic diacid [8].”
BackgroundXie, Y., Zhou, Q., He, Q., Wang, X., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.008 · Cited by 18
Marques, J. M., Nunes, R., Carvalho, A. M., Florindo, H. F., Ferreira, D., & Sarmento, B. F. C. C. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00173 · Cited by 16
Wen, J., Razick, A. A., How-Volkman, C., Bernstein, E., Nadora, D., Truong, A., Razick, D., Akhtar, M., Karabala, M., & Frezza, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16110 · Cited by 17
“18 This meticulous process ensures that approved biosimilars are safe for use and will match the effectiveness of their RPs.”
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 21
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Dai, S., Hong, H., Zhou, K., Zhao, K., Xie, Y., Li, C., Shi, J., Zhou, Z., Nie, L., & Wu, Z. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00032 · Cited by 16
Glycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Peptide Multimerization as Leads for Therapeutic Development
Sheard, D. E., Li, W., O’brien-simpson, N. M., Separovic, F., & Wade, J. D. (2021) · Biologics · doi:10.3390/biologics2010002 · Cited by 17
“The high specificity and affinity of peptide drugs have been a strong driving force behind their expansion as therapeutics [10], such as the initial discovery of the native hormone peptides insulin [11] and glucagon [12] to the subsequent development and production of more active synthetic peptide analogues [13,14].”
BackgroundZhang, G., Brown, J. S., Quartararo, A. J., Li, C., Tan, X., Hanna, S., Antilla, S., Cowfer, A. E., Loas, A., & Pentelute, B. L. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00625-3 · Cited by 18
Sinakos, E., Liava, C., & Loomba, R. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0704 · Cited by 19
“GLP-1 is an intestinal hormone, released from L cells in the small intestine in response to meals, that has multiple metabolic effects: it stimulates insulin secretion and inhibits glucagon secretion, increases energy disposal, delays gastric emptying and improves satiety [53].”
BackgroundInfluentialAdams, R., Joyce, C., Kuravsky, M. L., Harrison, K., Ahdash, Z., Balmforth, M. R., Chia, K., Marceddu, C., Coates, M. S., Snowden, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170357 · Cited by 17
“This approach has been used in a range of FDA approved peptide drugs, including the albumin-binding small molecule paclitaxel (14) and the glucagon-like peptide-1 agonist semaglutide, which contains an albumin-binding fatty acid moiety (15).”
BackgroundNo QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Demmel, V., Sandberg-Schaal, A., Jacobsen, J. B., Golor, G., Pettersson, J., & Flint, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0442-0 · Cited by 16
“The substitution at position 8 makes semaglutide less susceptible to degradation by dipeptidyl peptidase-4 (DPP-4), whereas improved albumin binding is facilitated through the lysine acylation and fatty diacid side chain [3].”
BackgroundHan, J. D. J., Chen, X., Zhao, L., Fu, J., Sun, L., Zhang, Y., Zhou, F. L., & Fei, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00336 · Cited by 17
Ichikawa, M., Hirayama, T., Fukushima, M., Kitazawa, I., Kojima, K., Sakai, T., Takatsu, Y., & Ohtaki, T. (2018) · ACS Omega · doi:10.1021/acsomega.8b00467 · Cited by 16
Yang, Q., Zhou, F. L., Tang, X., Wang, J., Feng, H., Jiang, W., Jin, L., Jiang, N., Yuan, Y., Han, J. D. J., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114214 · Cited by 18
Semaglutide Aggregates into Oligomeric Micelles and Short Fibrils in Aqueous Solution
Hamley, I. W., de Mello, L. R., Castelletto, V., Zinn, T., Cowieson, N. P., Seitsonen, J. J. T., & Bizien, T. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00342 · Cited by 16
Programmable Bio‐Derived Noncovalent Glass via Reconfigurable H‐Bonding Networks
Fan, W., Xing, R., Zhou, P., Shen, G., Cao, S., Yuan, C., & Yan, X. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202517982 · Cited by 16
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 21
“…of the half-life-extending technology was undertaken, most notably by introducing a C20 diacid that confers stronger binding affinity to human serum albumin (Box 1), and incorporating protection against DPP-IV cleavage, resulting in the discovery of the once-weekly analogue semaglutide 59 .”
InfluentialKweon, S., Lee, J.-H., Yang, S.-B., Park, S. J., Subedi, L., Shim, J., Cho, S., Choi, J. U., Byun, Y., Park, J., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00421-7 · Cited by 19
“In the case of liraglutide and semaglutide, lipidation was introduced into lysine at position 26 for albumin binding, but they showed lower GLP-1R binding (liraglutide K d = 0.11 nM, semaglutide K d = 0.38 nM) for a long half-life [54].”
BackgroundInfluentialHepatic function of glucagon-like peptide-1 and its based diabetes drugs
Feng, J. N., & Jin, T. (2024) · Medical Review · doi:10.1515/mr-2024-0018 · Cited by 18
“Semaglutide, commercially known as Ozem-pic ® , is a long-acting GLP-1RAs for T2D, approved in 2017, with a half-life ofseven days[45, 46].”
BackgroundNN1213 – A Potent, Long-Acting, and Selective Analog of Human Amylin
Dahl, K., Raun, K., Hansen, J. L., Poulsen, C., de la Cour, C. D., Clausen, T. R., Hansen, A. M. K., John, L. M., Plesner, A., Sun, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00022 · Cited by 17
Self-citationDouros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry
Yule, L. R., Bower, R. L., Kaur, H., Kowalczyk, R., Hay, D. L., & Brimble, M. A. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00850j · Cited by 15
Amyloidogenicity of peptides targeting diabetes and obesity
Lima, L. M. T. R., & Icart, L. P. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112157 · Cited by 16
Jensen, K. B., Mikkelsen, J. H., Jensen, S., Kidal, S., Friberg, G., Skrydstrup, T., & Gustafsson, M. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00528 · Cited by 15
Semaglutide for Weight Loss: Was It Worth the Weight?
Novograd, J., Mullally, J., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000430 · Cited by 16
“By slowing gastric emptying, the absorption of oral medications in the small intestine can be delayed by GLP-1RAs.”
BackgroundInfluentialKobayashi, D., Kuraoka, E., Hayashi, J., Yasuda, T., Kohmura, Y., Denda, M., Harada, N., Inagaki, N., & Otaka, A. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00161 · Cited by 15
de la Flor, J. C., Lorenzo, J. D., Marschall, A., Valga, F., Monzón, T., & Cícero, E. R. (2022) · Case Reports in Nephrology and Dialysis · doi:10.1159/000527919 · Cited by 15
Santiago, C. G., Paci, E., & Donnelly, D. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.110 · Cited by 15
Han, J. D. J., Huang, Y., Chen, X., Zhou, F. L., Fei, Y., & Fu, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.072 · Cited by 15
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“The first fatty diacid – derivatized peptide to offer once-weekly dosing and demonstrate significant weight loss was semaglutide [55].”
Li, W. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500289 · Cited by 16
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel
Saha, S., Banskota, S., Yousefpour, P., Schaal, J. L., Zakharov, N., Liu, J., Dzuricky, M. J., He, Z., Roberts, S., Li, X., et al. (2024) · Small Science · doi:10.1002/smsc.202400153 · Cited by 15
Kim, S. H., Kim, S. S., Kim, H. J., Park, E. J., & Na, D. H. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116682 · Cited by 16
GLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“The pharmacologic GLP-1RA semaglutide has been shown to bind GLP-1R with higher affinity than GLP-1 [76] and achieve nanomolar concentrations with pharmacologic interventions [77], suggesting that exogenous GLP-1R therapy may induce PKA-associated insulin secretion in pancreatic tissue that is not…”
A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands
Sicinski, K. M., Montanari, V., Raman, V. S., Doyle, J. R., Harwood, B. N., Song, Y. C., Fagan, M. P., Rios, M., Haines, D. R., Kopin, A. S., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01237 · Cited by 17
Mráziková, L., Neprašová, B., Mengr, A., Popelová, A., Strnadová, V., Holá, L., Železná, B., Kuneš, J., & Maletínská, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.779962 · Cited by 16
“The long-lasting anorexigenic effect of lipidized analogs of PrRP could be explained by their prolonged stability owing to binding to serum albumin, similar to liraglutide, semaglutide or palmitoylated gastric inhibitory polypeptide (Gault et al., 2011; Lau et al., 2015; Bech et al., 2017).”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Tricò, D., & Solini, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.002 · Cited by 15
Hayek, A. A., & Dawish, M. A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02053-0 · Cited by 15
“As a result, semaglutide has a half-life of approximately 1 week [14].”
BackgroundSolid‐Phase Thiol–Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist
Williams, E. T., Harris, P. W. R., Jamaluddin, A., Loomes, K. M., Hay, D. L., & Brimble, M. A. (2018) · Angewandte Chemie · doi:10.1002/ange.201805208 · Cited by 14
Hawkins, A., Joyce, C., Brady, K., Hold, A., Smith, A., Knight, M., Howard, C. J., van den Elsen, J. M. H., Lawson, A. D. G., & Macpherson, A. (2022) · mAbs · doi:10.1080/19420862.2022.2076295 · Cited by 16
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors
Lear, S., Amso, Z., & Shen, W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.008 · Cited by 16
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Trials · doi:10.1186/s13063-021-05442-y · Cited by 14
“Semaglutide is a human GLP-1 analogue that has 94% structural homology with native human GLP-1 and three important modifications [18] which extend its half-life in humans to approximately 1 week [18].”
BackgroundCyclic Peptide Linker Design and Optimization by Molecular Dynamics Simulations
Yu, L., Barros, S. A., Sun, C., & Somani, S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01359 · Cited by 16
Peng, D., Yang, L., Si, L., Zhu, B., Wu, P., Li, Y., Tang, D., Liu, Y., & Zhang, Y. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106477 · Cited by 17
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
“These structural modifications improved its binding with albumin and extended its half-life up to 7 days, allowing for once-weekly administration given subcutaneously [42].”
Li, X., Zhou, S., Tae, H., Wang, S., Li, T., Cai, W., Jiang, T., Adams, D. J., & Yu, R. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01758 · Cited by 13
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Rodaro, C., Tamaro, G., Faleschini, E., & Tornese, G. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448202.101 · Cited by 13
“A similar mechanism has been used in other drugs including insulin detemir [13], degludec [14], liraglutide, and semaglutide [15].”
Yeung, A. W. K., Hammerle, F. P., Behrens, S., Matin, M., Mickael, M., Litvinova, O., Parvanov, E. D., Kletečka-Pulker, M., & Atanasov, A. G. (2025) · JMIR Infodemiology · doi:10.2196/59767 · Cited by 15
“Semaglutide, the active ingredient in Ozempic, was developed in 2012 to treat type 2 diabetes [15].”
Cui, J., Zheng, Q., Weng, Y., Zhai, X., Su, Z. C., Du, Y., Wei, X., Yu, Y., Qu, Q., & Pan, M. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202501488 · Cited by 13
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.